Comcast Prevails in Part on Striking OpenTV Infringement Contentions

Jun 30, 2017

Reading Time : 2 min

This dispute began in October 2015 when OpenTV approached Comcast about licensing its patent portfolio because it believed certain Comcast products infringed its patents. In October 2016, Comcast filed a declaratory judgment action of non-infringement of ten patents in OpenTV’s portfolio. On March 27, 2017 OpenTV submitted its infringement contentions, which Comcast moved to strike on April 20. In its motion to strike, Comcast contends that OpenTV’s infringement contentions violate Rule 3-1 by: “(1) relying too much on ‘information and belief,’ (2) charting asserted claims for only one or two accused products despite purporting to accuse more products of infringement, (3) asserting indirect infringement theories in generic terms by merely tracking the pertinent statutory language, (4) using only boilerplate language to assert infringement under the doctrine of equivalents, and (5) failing to identify specifically the patent owners’ own ‘instrumentalities and products purportedly embodying [one of the asserted patents].’”

Comcast’s first argument relied on the language of Rule 3-1, which requires an infringement chart to specify where and how each limitation is found in the accused products. The court noted, however, that Rule 3-1 does not prohibit allegations made upon “information and belief.” The Rule distinguishes between identifying elements of the accused product alleged to practice a claim limitation and items of proof showing that the accused elements in fact practice the limitation. The court found that this distinction was appropriate given Comcast’s restriction of its source code and set-top boxes. The court ultimately rejected Comcast’s arguments that OpenTV’s contentions were vague and/or conclusory.

Comcast next argued that OpenTV failed to show that the claims and products charted in its contentions were appropriately representative of all accused products. The court agreed that OpenTV had not shown that all accused products shared the same characteristics as the allegedly representative ones. In fact, OpenTV’s proposed amended contentions called into question whether the originally-charted products were representative because OpenTV refused to limit the universe of accused products based on the characteristics that OpenTV previously alleged were common to all accused products. The court, therefore, did not grant OpenTV leave to amend its contentions to address whether the originally-charted products were representative.

Comcast also argued that OpenTV’s contentions concerning indirect infringement were conclusory and insufficient. OpenTV argued that it incorporated Comcast’s user manuals and screenshots of Comcast’s website to show how Comcast instructed its customers. OpenTV did not, however, expressly tie Comcast’s marketing materials to its allegations of direct infringement. The court found that including boilerplate language without describing what instructions led to what infringing behavior was not enough to disclose indirect infringement under Rule 3-1.

Finally1, Comcast argued OpenTV failed to disclose adequately its theory of infringement under the doctrine of equivalents. The court agreed.

The court granted Comcast’s motion, but did not do so with prejudice. Instead, the court permitted OpenTV to amend its infringement contentions to cure the deficiencies, consistent with the court’s opinion.

Comcast Cable Commc’ns, LLC v. OpenTV, Inc., No. C 16-06180 WHA (N.D. Cal. June 19, 2017).


1 Comcast also argued that OpenTV did not demonstrate that the patent owners’ own ‘instrumentalities and products purportedly embodying [one of the asserted patents].  But OpenTV withdrew this assertion, mooting this point.

Share This Insight

Previous Entries

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.